CRDF
Cardiff Oncology Inc
1.20$
-3.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 5.4% | 201.0% | 454.1% | 358.6% | 157.9% | 4,562.9% | 3,069.7% | 139.3% | 51.8% | 81.6% | 59.2% | 152.4% | |
| 94.6% | -101.0% | -354.1% | -258.6% | -57.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2,380.4% | 3,384.7% | 3,938.8% | 1,561.0% | 2,159.8% | 4,562.9% | 3,069.7% | 4,840.1% | 7,022.5% | 6,733.0% | 5,395.6% | 5,957.7% | |
| 2,075.0% | 2,530.4% | 3,012.1% | 2,276.6% | 2,117.9% | 2,354.9% | 2,245.1% | 3,297.5% | 3,414.8% | 2,672.7% | 1,827.5% | 2,398.7% | |
| 5,432.1% | 7,973.8% | 9,975.3% | 4,379.2% | 4,277.8% | 6,917.8% | 5,314.8% | 8,137.6% | 10,437.3% | 9,405.7% | 7,223.1% | 8,356.3% | |
| -5,337.5% | -8,074.8% | -10,536.7% | -5,068.5% | -4,511.4% | -6,817.8% | -5,214.8% | -8,037.6% | -10,337.3% | -9,305.7% | -7,123.1% | -8,256.3% | |
| 301.1% | 487.4% | 361.0% | 204.7% | 6.7% | 95.7% | 0.5% | 73.5% | 409.6% | – | – | – | |
| -5,116.1% | -8,776.7% | -10,289.8% | -4,932.1% | -4,354.8% | -6,709.7% | -5,275.1% | -7,880.5% | -10,026.9% | -8,492.0% | -6,651.7% | -7,732.0% | |
| 217.2% | 580.0% | -77.7% | 141.8% | 163.4% | -107.1% | -7.3% | -152.9% | -310.4% | 47.2% | -3.5% | – | |
| -5,116.1% | -8,776.7% | -10,289.8% | -4,932.1% | -4,354.8% | -6,709.7% | -5,275.1% | -7,880.5% | -10,026.9% | -8,492.0% | -6,651.7% | -7,732.0% | |
| -5,253.7% | -7,953.7% | -9,647.9% | -4,518.6% | -4,153.4% | -6,507.7% | -5,147.3% | -7,754.9% | -9,965.8% | -8,410.5% | -6,592.5% | -7,579.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.